Given negative muscle enzyme labs, a negative myositis autoantibody panel, normal electromyography, and fluctuating erythrocyte sedimentation rate and C‑reactive protein with symptom flare‑ups, should the patient be screened for other neuromuscular disorders such as mitochondrial or metabolic myopathies?

Muscle Biopsy is the Critical Next Step

Given the negative muscle enzymes, negative myositis antibodies, and normal EMG, you should proceed with muscle biopsy to screen for metabolic myopathies, mitochondrial disorders, and other noninflammatory neuromuscular conditions before abandoning the diagnostic workup. The fluctuating inflammatory markers with symptom flares suggest an underlying process that standard testing has not yet captured.

Why Muscle Biopsy is Essential in This Clinical Scenario

The combination of negative routine testing does not exclude treatable myopathies. Muscular dystrophy and mitochondrial myopathies should be included in the differential diagnosis in a patient presenting with proximal muscle weakness and elevated muscle enzyme levels—but importantly, these conditions can also present with normal or only intermittently elevated enzymes 1.

Key Diagnostic Considerations

Mitochondrial myopathies warrant specific attention in your patient:

• Classic histopathologic features include subsarcolemmal and interfibrillar accumulation of mitochondria visualized on Gomori trichrome stain showing "ragged red fibers" 1
• Reduction or absence of cytochrome c oxidase activity is characteristic 1
• These patients can present with episodic symptoms and fluctuating CK levels, as described in mitochondrial myopathy with episodic hyper-CK-emia (MIMECK), where infections or drugs trigger acute elevations 2

Metabolic myopathies including glycogen storage diseases must be considered:

• Pompe disease and other glycogen storage disorders (types IIIa, IV, V, VII) can present with muscle weakness and fluctuating CK 3
• Approximately 95% of late-onset Pompe patients have elevated CK, but some adults may have CK levels within normal reference range 3
• The differential includes Danon disease with its characteristic vacuolar glycogen storage 3

The Limitations of Your Current Testing

Normal EMG does not exclude myopathy:

• Inflammatory myopathies can present with negative EMG findings 4
• A 2024 case report documented necrotizing autoimmune myositis with negative EMG and negative autoantibodies, diagnosed only by muscle biopsy 4
• EMG sensitivity varies significantly across myopathy subtypes 5

Normal muscle enzymes occur in several treatable conditions:

• Dermatomyositis can present with isolated aldolase elevation and normal CK 6
• Some immune-mediated necrotizing myopathy (IMNM) patients present with asymptomatic hyperCKemia or chronic slowly progressive weakness resembling limb-girdle muscular dystrophy 7
• Late-onset Pompe disease may have normal CK in some cases 3

Specific Workup Algorithm

Step 1: Muscle Biopsy (Priority)

• Select a clinically weak muscle for biopsy 1
• Request comprehensive histochemical staining including:
  • Gomori trichrome for ragged red fibers (mitochondrial pathology) 1
  • Cytochrome c oxidase and succinate dehydrogenase staining 1, 2
  • Dystrophin staining to evaluate for muscular dystrophy 1
  • Acid phosphatase for glycogen storage diseases 3

Step 2: Specialized Enzyme Testing

• GAA enzyme activity measurement in lymphocytes or dried blood spot for Pompe disease—this is more reliable than muscle enzymes for diagnosis 3
• Urine glucose tetrasaccharide (Glc4) as a sensitive marker for Pompe and other glycogen storage diseases 3

Step 3: Genetic Testing Based on Biopsy Findings

• Dystrophin gene testing if muscular dystrophy features present 1
• Mitochondrial DNA sequencing if ragged red fibers or COX-deficient fibers identified 1, 2
• Targeted gene panels for limb-girdle muscular dystrophy (dysferlinopathies) 1

Step 4: Additional Metabolic Screening

• Thyroid function and parathyroid hormone to exclude endocrine myopathy 1
• Comprehensive medication review for drug-induced myopathy 1

Critical Pitfalls to Avoid

Do not dismiss the diagnosis based on negative initial testing. The muscle biopsy remains the gold standard for differentiating inflammatory from noninflammatory myopathy and is essential for subclassification 1. Recent evidence shows that IMNM can present with atypical histopathologic features including tubular aggregates, myofibrillar pathology, mitochondrial myopathy features, and excessive lipid accumulation 7.

The fluctuating ESR/CRP pattern is clinically significant and suggests an episodic inflammatory or metabolic process that standard autoimmune testing has not captured 2, 8. This pattern is consistent with mitochondrial myopathy with episodic hyper-CK-emia, where environmental triggers cause acute exacerbations 2.

Why This Matters for Morbidity and Mortality

Many of these conditions are treatable when identified early:

• Pompe disease has enzyme replacement therapy available 3
• Immune-mediated myopathies respond to immunosuppression when diagnosed correctly 8, 5
• Early treatment of IMNM significantly improves patient symptoms and outcomes 7
• Mitochondrial disorders benefit from supportive care and avoidance of triggers 2

Delaying muscle biopsy risks missing a treatable condition and allows progressive muscle damage that may become irreversible 1, 7.